A panel of expert medical professionals navigate the evolving landscape in biomarker testing for treating patients with metastatic colorectal cancer.
EP. 1: Social Determinants Contributing to Colorectal Cancer Risk
Ryan Haumschild, PharmD, MS, MBA, reviews risk factors for colorectal cancer, including social determinants and at-risk demographics.
EP. 2: Evaluating Clinical Burden of Metastatic Versus Nonmetastatic CRC
Dr Kristen Ciombor explores clinical impacts during the treatment of patients with metastatic or nonmetastatic colorectal cancer.
EP. 3: Exploring Advantages of Molecular Testing in CRC Treatment
Dr Kristen Ciombor discusses utilization of biomarkers and molecular testing in the treatment of patients with CRC.
EP. 4: Payer Considerations for Molecular Testing In Metastatic Colorectal Cancer
Dr Haumschild aligns payer considerations with molecular testing and biomarker application for treatment of patients with mCRC.
EP. 5: Navigating Clinical Pathways and Improved Sequencing Awareness in mCRC
In his final thoughts, Dr Haumschild outlines opportunities for next-generation sequencing in treatment for metastatic colorectal cancer.
EP. 6: Determining Appropriate mCRC Testing Strategies
Dr Ciombor provides her insight on determining appropriate testing strategies for patients with metastatic colorectal cancer.
EP. 7: Emphasizing HER2 Testing as A Premier Diagnostic Approach To mCRC
Testing prioritization and frequency are highlighted in Dr Ciombor’s final insights for this HER2 biomarker focus.
EP. 8: Identifying Appropriate Candidates for NGS Testing
Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC.
EP. 9: Identifying HER2 Overexpression in Patients with mCRC
Kanwal Raghav, MD, MBB, examines unmet needs in next-generation sequencing and barriers to coverage in this metastatic colorectal cancer discussion.
EP. 10: Key US-Based HER2 CRC Clinical Trials
Kanwal Raghav, MD, MBBS, references several HER2 clinical trials, each presenting unique drug combinations to address metastatic colorectal cancer.
EP. 11: Effects of Chemotherapy on HER2+ Targeted Therapy Outcomes
HER2+ targeted therapy outcomes are evaluated, particularly when combined with prior or subsequent chemotherapy.
EP. 12: Uptake of HER2 Therapy in mCRC
Kanwal Raghav, MD, MBBS, provides his closing insights, with a focus on HER2-targeted therapy uptake in metastatic colorectal cancer.
2 Clarke Drive Cranbury, NJ 08512